

CORRECTION

Open Access



# Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Martina S. J. McDermott<sup>1</sup>, Brigid C. Browne<sup>2</sup>, Neil T. Conlon<sup>1</sup>, Neil A. O'Brien<sup>3</sup>, Dennis J. Slamon<sup>3</sup>, Michael Henry<sup>1</sup>, Paula Meleady<sup>1</sup>, Martin Clynes<sup>1</sup>, Paul Dowling<sup>1,4</sup>, John Crown<sup>1,5</sup> and Norma O'Donovan<sup>1\*</sup>

**Correction: Mol Cancer 13, 157 (2014)**  
<https://doi.org/10.1186/1476-4598-13-157>

Following publication of the original article [1], a reader reported that “two signals in Fig. 3C seem to be unexpectedly similar”, and as original blots are no longer available (only cropped versions of the triplicate blots), an alternative replicate of the Fig. 3c blot is provided in this correction. This replacement does not alter the results presented in the text. The correct figure is given below.

Published online: 30 October 2023

The original article can be found online at <https://doi.org/10.1186/1476-4598-13-157>.

\*Correspondence:

Norma O'Donovan  
Norma.ODonovan@dcu.ie

<sup>1</sup> Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland

<sup>2</sup> Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research Sydney, Sydney, NSW, Australia


<sup>3</sup> Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

<sup>4</sup> Department of Biology, National University of Ireland, Maynooth, Maynooth, Co, Kildare, Ireland

<sup>5</sup> Department of Medical Oncology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 3** mTOR and eEF2k mediated regulation of eEF2 phosphorylation. **A** Immunoblot analysis of total and phosphorylated mTOR<sup>(Ser2448)</sup> in SKBR3-par and SKBR3-L cells following 24 h. lapatinib treatment. **B** Effect of rapamycin on growth of SKBR3-par and SKBR3-L cells. Error bars represent the mean ± SD (n = 3). **C** Immunoblot analysis of total and phosphorylated eEF2<sup>(Thr56)</sup> following 24 h. treatment with lapatinib and/or rapamycin. **D** Immunoblot analysis of total and phosphorylated eEF2k<sup>(Ser366, 359)</sup> in SKBR3-par and SKBR3-L cells following 24 h. lapatinib treatment. **E** Immunoblot examining the effect of NH125 alone and in combination with lapatinib on the phosphorylation of eEF2<sup>(Thr56)</sup> in SKBR3-par cells. \*denotes  $p \leq 0.05$

**Reference**

1. McDermott MSJ, Browne BC, Conlon NT, et al. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. *Mol Cancer*. 2014;13:157. <https://doi.org/10.1186/1476-4598-13-157>.